Starcoin Group (HKSE:00399) Other Stockholders Equity: HK$471.09 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Starcoin Group Other Stockholders Equity?

Starcoin Group HKSE:00399 Other Stockholders Equity is HK$471.09 Mil as of Sep. 2025. The stock has 7 warning signs investors should review.

Starcoin Group's Other Stockholders Equity for the quarter that ended in Sep. 2025 was HK$471.09 Mil.

Starcoin Group's quarterly Other Stockholders Equity increased from Sep. 2024 (HK$420.11 Mil) to Mar. 2025 (HK$536.97 Mil) but then declined from Mar. 2025 (HK$536.97 Mil) to Sep. 2025 (HK$471.09 Mil).

Starcoin Group's annual Other Stockholders Equity increased from Mar. 2023 (HK$-809.72 Mil) to Mar. 2024 (HK$400.33 Mil) and increased from Mar. 2024 (HK$400.33 Mil) to Mar. 2025 (HK$536.97 Mil).

Starcoin Group Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Starcoin Group's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starcoin Group Other Stockholders Equity Chart

Starcoin Group Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -609.99 -564.01 -809.72 400.33 536.97

Starcoin Group Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 579.59 400.33 420.11 536.97 471.09

Starcoin Group Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of HK$471.09 Mil mean?
Starcoin Group (HKSE:00399) has a Other Stockholders Equity of HK$471.09 Mil as of Sep. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Starcoin Group and its competitors.
Is Starcoin Group's Other Stockholders Equity too high?
Starcoin Group's current Other Stockholders Equity is HK$471.09 Mil.
How does Starcoin Group's Other Stockholders Equity compare to CASY and WSM?
Starcoin Group's Other Stockholders Equity of HK$471.09 Mil can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Retail - Cyclical company?
A good Other Stockholders Equity depends on the Retail - Cyclical industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Starcoin Group and its competitors. Starcoin Group's current Other Stockholders Equity is HK$471.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starcoin Group stock overvalued right now?
Starcoin Group (HKSE:00399) has a current Other Stockholders Equity of HK$471.09 Mil. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.07 — trading 21.7% above its estimated fair value. The current Other Stockholders Equity is HK$471.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Starcoin Group (HKSE:00399), the current Other Stockholders Equity is HK$471.09 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Starcoin Group Business Description

Address 145 Hennessy Road, Unit No. 2002, 20th Floor, On Hong Commercial Building, Wan Chai, Hong Kong, HKG
Starcoin Group Ltd, formerly Innovative Pharmaceutical Biotech Ltd is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The company has two operating segments; Trading of beauty products in Hong Kong and Research, development, and commercialisation of the oral insulin product. The company generates almost all of its revenue from Hong Kong.